December 16, 2011
Bernstein Liebhard LLP is investigating whether the Board of Directors of ISTA Pharmaceuticals, Inc. (“ISTA” or the “Company”) (Nasdaq: ISTA) is breaching its fiduciary duty to its shareholders in failing to embrace premium offers for the company by Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals”).
As reported, ISTA shareholders would receive $6.50 in cash for each share they own. The investigation is focused on ISTA’s
failing to embrace Valeant Pharmaceuticals’ offers.
Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last nine years.